Rituximab biosimilar (Intas Biopharmaceuticals)

利妥昔单抗生物类似药（Intas Biopharmaceuticals）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Intas Biopharmaceuticals)

Drug Alias Name利妥昔单抗生物仿制药（Intas Biopharmaceuticals）Mabtas

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2013/01/01

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesIntas Biopharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesIntas Biopharmaceuticals

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02